Table 2.
The pooled associations between VDR expression and the prognosis of patients with breast cancer
| Outcome subgroup | Study number | Case number | HR (95%CI)-model | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (%) | P | |||||
| OS | 6 | 1681 | 0.82 (0.64–1.06)-random | 0.052 | 69.2 | 0.006 |
| Country | ||||||
| Germany | 4 | 471 | 0.80 (0.58–1.10)- random | 0.161 | 763 | 0.005 |
| Others | 2 | 1210 | 0.71 (0.27–1.88)-random | 0.488 | 70.7 | 0.065 |
| Pathological type | ||||||
| Invasive ductal | 1 | 82 | 0.49 (0.12–1.97) | 0.315 | – | – |
| Others | 5 | 1599 | 0.83 (0.64–1.08)- random | 0.168 | 74.1 | 0.004 |
| Molecular type | ||||||
| Triple negative | 1 | 96 | 0.37 (0.13–1.08) | 0.066 | – | – |
| Multiple | 5 | 1585 | 0.85 (0.67–1.10)-random | 0.229 | 70.1 | 0.010 |
| Staining location | ||||||
| Nucleus | 4 | 1503 | 0.87 (0.68–1.12)-random | 0.293 | 76.1 | 0.006 |
| Nucleus and cytoplasm | 2 | 178 | 0.41 (0.18–0.95)-fixed | 0.038 | 0 | 0.753 |
| Cut-off value | ||||||
| IRS > 5 | 2 | 1196 | 0.98 (0.67–1.45)- fixed | 0.931 | 7.3 | 0.299 |
| IRS > 25 | 2 | 272 | 0.94 (0.70–1.26)-random | 0.664 | 82.7 | 0.016 |
| Others | 2 | 213 | 0.47 (0.30–0.74)- fixed | 0.001 | 0 | 0.613 |
| DFS | 5 | 594 | 1.11 (0.73–1.70)- random | 0.625 | 72.7 | 0.005 |
| CSS | 2 | 1792 | 0.78 (0.42–1.46)- random | 0.439 | 73.4 | 0.052 |
| PFS | 1 | 1114 | 1.14 (0.87–1.50) | 0.346 | – | – |
VDR Vitamin D receptor, OS Overall survival, IRS Immunoreactive score, DFS Disease-free survival, CSS Cancer-specific survival, PFS Progression-free survival, HR Hazard ratio, CI Confidence interval